Skandinaviska Enskilda Banken AB publ Sells 10,467 Shares of Pfizer Inc. (NYSE:PFE)

Skandinaviska Enskilda Banken AB publ lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 0.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,138,537 shares of the biopharmaceutical company’s stock after selling 10,467 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Pfizer were worth $30,103,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Swedbank AB increased its stake in Pfizer by 0.7% during the 3rd quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock valued at $166,284,000 after purchasing an additional 37,636 shares in the last quarter. United Bank grew its holdings in shares of Pfizer by 3.7% during the third quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock valued at $1,030,000 after buying an additional 1,277 shares during the last quarter. Entropy Technologies LP bought a new stake in shares of Pfizer during the third quarter worth about $860,000. GSA Capital Partners LLP raised its holdings in shares of Pfizer by 87.6% in the 3rd quarter. GSA Capital Partners LLP now owns 32,786 shares of the biopharmaceutical company’s stock worth $949,000 after acquiring an additional 15,310 shares during the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd lifted its position in Pfizer by 52.6% in the 3rd quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 31,723 shares of the biopharmaceutical company’s stock valued at $919,000 after acquiring an additional 10,938 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Trading Down 0.4 %

Shares of PFE stock opened at $25.60 on Friday. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The company has a 50 day moving average of $26.26 and a 200-day moving average of $27.17. The firm has a market cap of $145.08 billion, a P/E ratio of 18.16, a PEG ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the prior year, the firm earned $0.10 earnings per share. The company’s revenue was up 24.7% compared to the same quarter last year. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on PFE. Wolfe Research started coverage on Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective for the company. Bank of America reiterated a “neutral” rating and set a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Citigroup dropped their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. UBS Group reduced their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Finally, StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.